What is the clinical evidence from this study?

Study design: Other. Population: Dilated cardiomyopathy (n=2). Intervention: iPSC reprogramming. Primary outcome: Successful characterization of iPSC lines including expression of pluripotency markers and confirmation of mutations.

What type of study is this?

This is a Cohort Study study (also classified as: In Vitro Study).

October 9, 2025Circulation Research

Abstract Wed033: Characterization of iPSC lines from dilated cardiomyopathy patients carrying a mutation in the RBM20 gene

View Full Paper

Ask AI

Bookmark

Key result

Patient-derived blood cells yield viable iPSC models for RBM20-mutated dilated cardiomyopathy.

Population

Peripheral blood mononuclear cells isolated from two patients with dilated cardiomyopathy carrying RBM20…

Design

Preclinical

Authors

SRSnekha RajasekaranUniversity of Alabama at Birmingham AMAmit ManhasCardiovascular Institute of the South NSNazish SayedCardiovascular Institute of the South

Discussion

Member takes

Implication

The successful generation of iPSC lines from DCM patients with RBM20 mutations provides a valuable in vitro model for studying disease pathophysiology and drug screening.

Key Points

The study successfully established induced-pluripotent stem cell lines from dilated cardiomyopathy patients with RBM20 mutations.
Using RT-qPCR and immunofluorescence, pluripotency markers SOX2, NANOG, and OCT3/4 were confirmed in iPSCs after one week.
Karyotyping analysis showed no chromosomal abnormalities in iPSC lines, indicating their potential as a reliable model for studying DCM.
The findings highlight the utility of these patient-derived iPSCs in understanding the pathophysiology of dilated cardiomyopathy.

Structured PICO

Population

Two patients with dilated cardiomyopathy carrying specific RBM20 mutations (c.1901G>A and c.3595G>A) whose peripheral blood mononuclear cells were reprogrammed into iPSCs.

Exposure

Reprogramming using Sendai virus vectors to induced-pluripotent stem cell (iPSC) lines

Outcome

Expression of pluripotency markers (SOX2, NANOG, OCT3/4), germ layer formation, and confirmation of RBM20-specific mutationssurrogate

The successful generation of iPSC lines from DCM patients with RBM20 mutations provides a valuable in vitro model for studying disease pathophysiology and drug screening.

Cite This Study

Rajasekaran et al. (2025) studied Dilated cardiomyopathy (n=2). iPSC reprogramming was evaluated on Successful characterization of iPSC lines including expression of pluripotency markers and confirmation of mutations. Peripheral blood mononuclear cells from two patients with dilated cardiomyopathy carrying RBM20 mutations were successfully reprogrammed into iPSC lines expressing pluripotency markers with normal karyotypes.

synapsesocial.com/papers/68e80eb363e2e2f707877dba https://doi.org/10.1161/res.137.suppl_1.wed033

View Full Paper

Ask AI

Bookmark

Implication

The successful generation of iPSC lines from DCM patients with RBM20 mutations provides a valuable in vitro model for studying disease pathophysiology and drug screening.

Abstract Wed033: Characterization of iPSC lines from dilated cardiomyopathy patients carrying a mutation in the RBM20 gene

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Abstract Wed033: Characterization of iPSC lines from dilated cardiomyopathy patients carrying a mutation in the RBM20 gene

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider